SMS Lifesciences India posts Q1 FY24 consolidated loss at Rs. 1.79 Cr
The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023
The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
This product will be launched through Granules Consumer Health (GCH) division
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Subscribe To Our Newsletter & Stay Updated